BRIEF: CANbridge raises $26 million in share sale to WuXi Bio at 14.7% discount
Rare disease drugmaker CANbridge Pharmaceuticals Inc. (1228.HK) announced on Monday that it will sell 84.03 million new shares to WuXi Biologics HealthCare Venture, a subsidiary of WuXi Biologics (2269.HK), for…
Investors pile into CANbridge stock but can the rally last?
The maker of drugs for rare diseases has enjoyed an explosive rise in its share price, helped by a partnership deal and Chinese moves to widen access to costly therapies…
B&K Corp eyes IPO to keep its slow-developing drugs alive
The company focuses on wound-healing PDGF drugs and its core product, Pro-101-2, isn’t expected to enter Phase 3 clinical trials for at least three more years Key Takeaways: B&K lost…
Jiangsu Recbio Shoots to Become Hong Kong’s First HPV Vaccine Stock
The vaccine producer is making a second attempt to list in Hong Kong, as its core HPV vaccine undergoes Phase 3 clinical trials Key takeaways: Jiangsu Recbio has filed a…
